Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
MAbs
; 7(3): 630-7, 2015.
Article
em En
| MEDLINE
| ID: mdl-25751241
Palavras-chave
AUC, area under the concentration vs time curve; AVM, arterovenous malformations; CI, cardiac index; ELISA, enzyme-linked immunosorbent assay; HHT, hereditary hemorrhagic telangectasia; IIV, interindividual variability; IgG, immunoglobulin G; PK-PD, pharmacokinetic-pharmacodynamic; TGF-ß, transforming growth factor ß; TMDD, target-mediated drug disposition; VEGF, vascular endothelial growth factor; angiogenesis factors; angiogenic; antiangiogenesis agents; bevacizumab; dose-response relationship; hereditary hemorrhagic telangiectasia; pharmacokinetics
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Telangiectasia Hemorrágica Hereditária
/
Inibidores da Angiogênese
/
Bevacizumab
/
Modelos Biológicos
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
MAbs
Assunto da revista:
ALERGIA E IMUNOLOGIA
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
França